Univentricular heart and Fontan staging: analysis of factors impacting on body growth

Eur J Cardiothorac Surg. 2012 Jun;41(6):e139-45. doi: 10.1093/ejcts/ezs194.

Abstract

Objectives: The optimal timing of the Fontan staging for a univentricular heart and its impact on growth remains debateable. In a Fontan cohort, the influence of staged interventions and patient factors on somatic development was explored.

Methods: We reviewed 64 total cavopulmonary connection (TCPC) patients treated since 1992. Serial anthropometric parameters recorded from birth to the latest follow-up (mean 12.5 ± 6.1 years) and at each intervention [neonatal surgery, bidirectional cavopulmonary anastomosis (BCPA), TCPC, catheter treatment] were converted to z-scores. The influence of saturation, heart failure treatment and surgery intervals on growth was determined.

Results: The mean z-scores for weight and height changed significantly at each surgery up to the TCPC (-0.3 ± 1.2 and 0 ± 1 at birth, -1.3 ± 1.9 and -0.9 ± 1.7 at neonatal surgery, -2.1 ± 1.2 and -1.6 ± 1.3 at the BCPA, -1.2 ± 1.3 and -0.7 ± 1.4 at the TCPC for weight and height, respectively; P < 0.05 for each interval), with the largest decline before the BCPA, and the most marked improvement before the TCPC. Z-scores did not change significantly after the TCPC. Younger age at the BCPA had a positive influence on the weight z-score at the TCPC (P < 0.05); somatic growth at the latest follow-up (FU) was negatively influenced by heart failure treatment (P < 0.05).

Conclusions: Body growth is severely impaired in Fontan patients. A close interstage follow-up between the first surgery and the BCPA must be targeted at optimizing nutritional support to counter the important growth retardation occurring before the BCPA. The better catch-up growth at the TCPC when the BCPA is performed earlier in life supports the current trend to perform the BCPA at a younger age. Heart failure treatment after a Fontan completion is independently associated with decreased late somatic development.

MeSH terms

  • Age Factors
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Anthropometry / methods
  • Body Height / drug effects
  • Body Height / physiology
  • Body Weight / drug effects
  • Body Weight / physiology
  • Child, Preschool
  • Female
  • Fontan Procedure / adverse effects*
  • Fontan Procedure / methods
  • Growth Disorders / etiology*
  • Growth Disorders / physiopathology
  • Heart Ventricles / abnormalities*
  • Heart Ventricles / surgery
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Retrospective Studies
  • Risk Factors

Substances

  • Angiotensin-Converting Enzyme Inhibitors